Xilio Therapeutics (NASDAQ:XLO) Issues Quarterly Earnings Results

Xilio Therapeutics (NASDAQ:XLO) released its earnings results on Tuesday. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02, Zacks reports.

Xilio Therapeutics Stock Performance

Shares of XLO opened at $0.84 on Tuesday. The stock has a 50-day moving average of $0.95 and a two-hundred day moving average of $0.94. The stock has a market cap of $37.14 million, a P/E ratio of -0.49 and a beta of -0.38. Xilio Therapeutics has a one year low of $0.58 and a one year high of $1.93.

About Xilio Therapeutics

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.